Investigational drug · Phase 3
ABP-671
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease, Gout.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
8
Any phase or sponsor naming "ABP-671"
First trial start
2023
Aug 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABP-671", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
- Gout
Approved drugs for the same conditions: Gout · Chronic kidney disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABP-671" as an intervention, largest first.
- Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With GoutPivotal-lookingCompleted
Atom Therapeutics Co., LtdIndustry
NCT05818085 · 300 participants · Start Aug 11, 2023 · Primary completion Jan 30, 2025
Drug: ABP-671; Allopurinol · For: Gout
Sites: Tempe, Arizona; Tuscon, Arizona; Anaheim, California · 57 sites in all
Atom Therapeutics Co., LtdIndustry
NCT07323095 · 80 participants (planned) · Start Oct 2, 2026 · Primary completion Oct 31, 2027
Drug: ABP-671 plus febuxostat Group 1; ABP-671 plus febuxostat Group 2 and 2 more · For: Chronic Kidney Disease
Sites: Gosford, Australia; Newcastle, Australia; Brisbane, Australia · 10 sites in all
Atom Therapeutics Co., LtdIndustry
NCT04638543 · 60 participants · Start Nov 27, 2020 · Primary completion Oct 26, 2021
Drug: ABP-671; Placebo · For: Gout; Hyperuricemia
Sites: Canberra, Australia; Kanwal, Australia; Kippa-Ring, Australia · 5 sites in all
- Extension Study of ABP-671 in Participants With GoutPivotal-lookingTerminated
Atom Therapeutics Co., LtdIndustry
NCT06276556 · 43 participants · Start Apr 22, 2024 · Primary completion Sep 5, 2024
Drug: ABP-671; Allopurinol · For: Gout
Sites: Tempe, Arizona; Tucson, Arizona; Anaheim, California · 54 sites in all
Atom Therapeutics Co., LtdIndustry
NCT03906006 · 32 participants · Start Oct 17, 2018 · Primary completion Jun 20, 2019
Drug: ABP-671 · For: Gout; Hyperuricemia
Sites: Tempe, Arizona
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671Completed
Atom Therapeutics Co., LtdIndustry
NCT04060173 · 27 participants · Start Sep 5, 2019 · Primary completion Dec 29, 2019
Drug: ABP-671 · For: Hyperuricemia; Gout
Sites: Tempe, Arizona
Atom Therapeutics Co., LtdIndustry
NCT07367971 · 22 participants · Start Jan 23, 2026 · Primary completion Aug 19, 2026
Drug: ABP-671 plus allopurinol · For: Gout Chronic; Gout; DDI (Drug-Drug Interaction)
Sites: Cary, North Carolina
Atom Therapeutics Co., LtdIndustry
NCT04303039 · 12 participants · Start May 22, 2020 · Primary completion Jun 9, 2020
Drug: ABP-671 · For: Gout; Food-drug Interaction
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671 in healthy participants and patients with hyperuricemia and gout: a proof-of-concept study.
Wang J, Zhang L, Schwertschlag U, et al. · Arthritis Res Ther 2026
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects.
Gurwith M, Wu RJ, Schwertschlag U, et al. · Drug Des Devel Ther 2025
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.